Back
OncoCyte 10K Form
Sell
43
OCX
OncoCyte
Last Price:
2.65
Seasonality Move:
36.67%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-04-28 | 10K | OCX/OncoCyte Annual |
2020-03-26 | 10K | OCX/OncoCyte Annual |
2019-11-14 | 10Q | OCX/OncoCyte Quarterly |
2019-08-14 | 10Q | OCX/OncoCyte Quarterly |
2019-05-14 | 10Q | OCX/OncoCyte Quarterly |
2019-04-30 | 10K | OCX/OncoCyte Annual |
Receive OCX News And Ratings
See the #1 stock for the next 7 days that we like better than OCX
OCX Financial Statistics
Sales & Book Value
Annual Sales: | $1.5M |
---|---|
Cash Flow: | $-5.64M |
Price / Cash Flow: | 0 |
Annual Sales: | $0.73 |
Price / Book: | 4.56 |
Profitability
EPS (TTM): | -4.54000 |
---|---|
Net Income (TTM): | $-43.14M |
Gross Margin: | $413K |
Return on Equity: | -211.42% |
Return on Assets: | -57.93% |
OncoCyte Earnings Forecast
Key OncoCyte Financial Ratios
- The Gross Profit Margin over the past 5 years for OCX is 27.48%.
- The Selling, General & Administrative Expenses for OCX have been equal to 900.60% of Gross Profit Margin.
- The Research & Development expenses have been 618.36% of Revenue.
- The Interest Expense is -0.19% of Operating Income.
- The Net Earning history of OCX is -1,848.37% of Total Revenues.
- Per Share Earnings over the last 11 years have been positive in 4 years.
OncoCyte Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Biotechnology |
Sector: | Health Care |
Current Symbol: | OCX |
CUSIP: | 68235C |
Website: | oncocyte.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 0.53 |
Quick Ratio: | 0.39 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |